PURPOSE: Renal cell carcinoma belongs among the deadliest malignancies despite great progress in therapy and accessibility of primary care. One of the main unmet medical needs remains the possibility of early diagnosis before the tumor dissemination and prediction of early relapse and disease progression after a successful nephrectomy. In our study, we aimed to identify novel diagnostic and prognostic biomarkers using next-generation sequencing on a novel cohort of RCC patients. METHODS: Global expression profiles have been obtained using next-generation sequencing of paired tumor and non-tumor tissue of 48 RCC patients. Twenty candidate lncRNA have been selected for further validation on an independent cohort of paired tumor and non-tumor tissue of 198 RCC patients. RESULTS: Sequencing data analysis showed significant dysregulation of more than 2800 lncRNAs. Out of 20 candidate lncRNAs selected for validation, we confirmed that 14 of them are statistically significantly dysregulated. In order to yield better discriminatory results, we combined several best performing lncRNAs into diagnostic and prognostic models. A diagnostic model consisting of AZGP1P1, CDKN2B-AS1, COL18A1, and RMST achieved AUC 0.9808, sensitivity 95.96%, and specificity 90.4%. The model for prediction of early relapse after nephrectomy consists of COLCA1, RMST, SNHG3, and ZNF667-AS1 and achieved AUC 0.9241 with sensitivity 93.75% and specificity 71.07%. Notably, no combination has outperformed COLCA1 alone. Lastly, a model for stage consists of ZNF667-AS1, PVT1, RMST, LINC00955, and TCL6 and achieves AUC 0.812, sensitivity 85.71%, and specificity 69.41%. CONCLUSION: In our work, we identified several lncRNAs as potential biomarkers and developed models for diagnosis and prognostication in relation to stage and early relapse after nephrectomy.

Faculty of Medicine Department of Biology Masaryk University Kamenice 753 5 625 00 Brno Czech Republic

Masaryk Memorial Cancer Institute Department of Comprehensive Cancer Care Faculty of Medicine Masaryk University Zluty Kopec 543 7 602 00 Brno Czech Republic

Masaryk University Central European Institute of Technology Kamenice 753 5 625 00 Brno Czech Republic

Zobrazit více v PubMed

Andrews S (2010) FastQC: a quality control tool for high throughput sequence data

Angenard G, Merdrignac A, Louis C, et al. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma. Dig Liver Dis off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2019;51:1337–1343. doi: 10.1016/j.dld.2019.03.019. PubMed DOI

Bhan A, Soleimani M, Mandal SS. Long non-coding RNA (LncRNA) and cancer: a new paradigm. Cancer Res. 2017;77:3965–3981. doi: 10.1158/0008-5472.CAN-16-2634. PubMed DOI PMC

Bohosova J, Kubickova A, Slaby O. lncRNA PVT1 in the pathogenesis and clinical management of renal cell carcinoma. Biomolecules. 2021;11:664. doi: 10.3390/biom11050664. PubMed DOI PMC

Bohosova J, Kasik M, Kubickova A, et al. LncRNA PVT1 is increased in renal cell carcinoma and affects viability and migration in vitro. J Clin Lab Anal. 2022;36:e24442. doi: 10.1002/jcla.24442. PubMed DOI PMC

Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84. doi: 10.1016/j.eururo.2018.08.036. PubMed DOI PMC

Chandra Gupta S, NandanTripathi Y. Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets. Int J Cancer. 2017;140:1955–1967. doi: 10.1002/ijc.30546. PubMed DOI

Chen Z, Zhuang Q, Cheng K, et al. Long non-coding RNA TCL6 enhances preferential toxicity ofpaclitaxel to renal cell carcinoma cells. J Cancer. 2020;11:1383–1392. doi: 10.7150/jca.32552. PubMed DOI PMC

Chen X, Liu K, Xu W, et al. Tumor-related molecular regulatory mechanisms of long non-coding RNA RMST: recent evidence. Mini Rev Med Chem. 2022;22:1374–1379. doi: 10.2174/1389557521666211202150646. PubMed DOI

Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8:1015. doi: 10.3390/cells8091015. PubMed DOI PMC

Dasgupta P, Kulkarni P, Majid S, et al. LncRNA CDKN2B-AS1/miR-141/cyclin D network regulates tumor progression and metastasis of renal cell carcinoma. Cell Death Dis. 2020;11:660. doi: 10.1038/s41419-020-02877-0. PubMed DOI PMC

Davis MPA, van Dongen S, Abreu-Goodger C, et al. Kraken: a set of tools for quality control and analysis of high-throughput sequence data. Methods. 2013;63:41–49. doi: 10.1016/j.ymeth.2013.06.027. PubMed DOI PMC

Decastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am. 2008;35(581–592):vi. doi: 10.1016/j.ucl.2008.07.005. PubMed DOI

Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinforma Oxf Engl. 2013;29:15–21. doi: 10.1093/bioinformatics/bts635. PubMed DOI PMC

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol off J Eur Soc Med Oncol. 2019;30:706–720. doi: 10.1093/annonc/mdz056. PubMed DOI

Gao S, Wang Z. Comprehensive analysis of regulatory network for LINC00472 in clear cell renal cell carcinoma. J Healthc Eng. 2021;2021:3533608. doi: 10.1155/2021/3533608. PubMed DOI PMC

He H-T, Xu M, Kuang Y, et al. Biomarker and competing endogenous RNA potential of tumor-specific long noncoding RNA in chromophobe renal cell carcinoma. OncoTargets Ther. 2016;9:6399–6406. doi: 10.2147/OTT.S116392. PubMed DOI PMC

Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 2011;12:323. doi: 10.1186/1471-2105-12-323. PubMed DOI PMC

Li W-Q, Pfeiffer RM, Hyland PL, et al. Genetic polymorphisms in the 9p21 region associated with risk of multiple cancers. Carcinogenesis. 2014;35:2698–2705. doi: 10.1093/carcin/bgu203. PubMed DOI PMC

Liu Z, Li M, Hua Q, et al. Identification of an eight-lncRNA prognostic model for breast cancer using WGCNA network analysis and a Cox-proportional hazards model based on L1-penalized estimation. Int J Mol Med. 2019;44:1333–1343. doi: 10.3892/ijmm.2019.4303. PubMed DOI PMC

Liu Y, Wang J, Shou Y, et al. Restoring the epigenetically silenced lncRNA COL18A1-AS1 represses ccRCC progression by lipid browning via miR-1286/KLF12 axis. Cell Death Dis. 2022;13:578. doi: 10.1038/s41419-022-04996-2. PubMed DOI PMC

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014 doi: 10.1186/s13059-014-0550-8. PubMed DOI PMC

Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11:79–87. doi: 10.14740/wjon1279. PubMed DOI PMC

Qi-Dong X, Yang X, Lu J-L, et al. Development and validation of a nine-redox-related long noncoding RNA signature in renal clear cell carcinoma. Oxid Med Cell Longev. 2020;2020:6634247. doi: 10.1155/2020/6634247. PubMed DOI PMC

Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17:47–62. doi: 10.1038/nrg.2015.10. PubMed DOI

Rysz J, Konecki T, Franczyk B, et al. The Role of Long Noncoding RNA (lncRNAs) Biomarkers in Renal Cell Carcinoma. Int J Mol Sci. 2022;24:643. doi: 10.3390/ijms24010643. PubMed DOI PMC

Vrba L, Futscher BW. Epigenetic silencing of lncRNA MORT in 16 TCGA cancer types. F1000Research. 2018;7:211. doi: 10.12688/f1000research.13944.1. PubMed DOI PMC

Wang Y, Li Z, Li W, et al. Prognostic significance of long non-coding RNAs in clear cell renal cell carcinoma: a meta-analysis. Medicine (baltimore) 2019;98:e17276. doi: 10.1097/MD.0000000000017276. PubMed DOI PMC

Wang S, Luo C, Li B, et al. LINC00472 inhibits cell migration by enhancing intercellular adhesion and regulates H3K27ac level via interacting with P300 in renal clear cell carcinoma. Cell Death Discov. 2022;8:454. doi: 10.1038/s41420-022-01243-7. PubMed DOI PMC

Wu J, Lin R, Zhang L, et al. LINC00887 Fosters development of clear cell renal cell carcinoma via inhibiting CD8+ T Cell immune infiltration. Comput Math Methods Med. 2022;2022:2582474. doi: 10.1155/2022/2582474. PubMed DOI PMC

Wu Z, Huang X, Cai M, Huang P. Potential biomarkers for predicting the overall survival outcome of kidney renal papillary cell carcinoma: an analysis of ferroptosis-related LNCRNAs. BMC Urol. 2022;22:152. doi: 10.1186/s12894-022-01037-0. PubMed DOI PMC

Xiang Z, Shen E, Li M, et al. Potential prognostic biomarkers related to immunity in clear cell renal cell carcinoma using bioinformatic strategy. Bioengineered. 2021;12:1773–1790. doi: 10.1080/21655979.2021.1924546. PubMed DOI PMC

Xie X, Lin J, Fan X, et al. LncRNA CDKN2B-AS1 stabilized by IGF2BP3 drives the malignancy of renal clear cell carcinoma through epigenetically activating NUF2 transcription. Cell Death Dis. 2021;12:201. doi: 10.1038/s41419-021-03489-y. PubMed DOI PMC

Xu Z, Ye J, Bao P, et al. Long non-coding RNA SNHG3 promotes the progression of clear cell renal cell carcinoma via regulating BIRC5 expression. Transl Cancer Res. 2021;10:4502–4513. doi: 10.21037/tcr-21-1802. PubMed DOI PMC

Xuan Y, Chen W, Liu K, et al. A risk signature with autophagy-related long noncoding RNAs for predicting the prognosis of clear cell renal cell carcinoma: based on the TCGA database and bioinformatics. Dis Markers. 2021;2021:8849977. doi: 10.1155/2021/8849977. PubMed DOI PMC

Yang K, Lu X-F, Luo P-C, Zhang J. Identification of six potentially long noncoding RNAs as biomarkers involved competitive endogenous RNA in clear cell renal cell carcinoma. BioMed Res Int. 2018;2018:9303486. doi: 10.1155/2018/9303486. PubMed DOI PMC

Yang W, Zhang K, Li L, et al. Discovery and validation of the prognostic value of the lncRNAs encoding snoRNAs in patients with clear cell renal cell carcinoma. Aging. 2020;12:4424–4444. doi: 10.18632/aging.102894. PubMed DOI PMC

Zhang C, Qu Y, Xiao H, et al. LncRNA SNHG3 promotes clear cell renal cell carcinoma proliferation and migration by upregulating TOP2A. Exp Cell Res. 2019;384:111595. doi: 10.1016/j.yexcr.2019.111595. PubMed DOI